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Dominican Partners with Biotech Firm for Project
The collaborative project, funded with a STTR (Small Business Technology Transfer) grant from
the National Institutes of Health (NIH), involves preclinical stage II development of a new
chloroquine analog, called a Reversed Chloroquine Compound (RCQ), a class of molecules
effective against multi-drug resistant forms of human malarias. The Dominican research team,
led by Dr. Roland Cooper, will evaluate the molecules supplied by DesignMedix for efficacy
against a variety of chloroquine-resistant strains of malaria.
The Dominican research team with DesignMedix also will evaluate the potential for malaria
strains to evolve resistance to the RCQ drugs. The project may also evaluate the drugs against ex
vivo samples of malaria from subjects in field studies in which Dominican researchers already
participate, and aid in the interpretation of sequencing results of genomes from RCQ-resistant
parasites.
“It creates opportunities for students to engage in cutting edge, federally-funded malaria research
at Dominican,” says Dr. Cooper, a biologist and associate professor who has been working on
anti-malarial drug research with colleagues at Portland State University since 2004. “That in
turns helps in recruiting students at the undergraduate and graduate levels who are especially
keen to engage in the growing research profile of the School of Health and Natural Sciences.”
Dr. Cooper has long collaborated with Dr. David Peyton, professor of Chemistry at Portland
State, who is the Chief Scientific Officer for DesignMedix. The company is pursuing drugs that
target microorganisms known to thwart chemotherapy by becoming resistant, such as malaria or
various bacterial species.
Dominican’s role is to explore the mechanism of action of these drugs in the malaria parasite by
trying to induce resistance to the compounds. Genetic changes associated with resistance often
point to proteins directly associated with the action of a drug.
In 2012, Dominican was involved in research with a UCSF malaria clinical drug trial in Uganda,
funded in part from President Mary Marcy’s Strategic Initiative grant. That work was important
in helping secure NIH funding for this current project, by providing key preliminary data on the
RCQs.
The Dominican research team partnering with DesignMedix’s team is grateful to Dominican
senior biology major Melissa Forbush, who has worked as an independent study student for two
years on the project. According to Dr. Cooper, she significantly advanced the project, providing
the platform for the new research to advance.
Forbush and graduate student Stephanie Huezo presented their malaria research last November at
the American Society of Tropical Medicine and Hygiene meeting in Washington, D.C.
Dr. Cooper said the DesignMedix project also provides funding to recruit an MS student in the
fall 2014.
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